Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NextCure Inc NXTC

Healthcare Biotechnology
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its... see more

Recent & Breaking News (NDAQ:NXTC)

NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

GlobeNewswire October 27, 2022

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

GlobeNewswire October 5, 2022

NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

GlobeNewswire October 4, 2022

NextCure to Present at the Ladenburg Thalmann Healthcare Conference

GlobeNewswire September 22, 2022

NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation

GlobeNewswire July 6, 2022

NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

GlobeNewswire June 27, 2022

Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting

GlobeNewswire June 22, 2022

NextCure to Present at the JMP Securities Life Sciences Conference

GlobeNewswire June 8, 2022

NextCure Provides Business Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 5, 2022

NextCure to Present at the BofA Securities 2022 Healthcare Conference

GlobeNewswire May 3, 2022

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

GlobeNewswire April 19, 2022

NextCure to Present at 21st Annual Needham Virtual Healthcare Conference

GlobeNewswire April 5, 2022

NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 3, 2022

NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 8, 2022

NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

GlobeNewswire December 13, 2021

NextCure to Present at The JMP Securities Hematology and Oncology Summit

GlobeNewswire November 30, 2021

NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

GlobeNewswire November 22, 2021

NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting

GlobeNewswire November 13, 2021

NextCure Reports Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire November 4, 2021